HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects-Reference-Cited by-同舟云学术

HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects

Published:2022-05 Issue:3 Volume:36 Page:393-409
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Yang Jingjing,Lin Lili,Long Qihe,Zhang Qian,Sun Guilan,Zhou Liang,Wang Qingyu,Zhu Jun,Li Fanfan,Hu Wei^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-022-00534-w.pdf

Reference22 articles.

1. Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, et al. Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022;104: 102339. https://doi.org/10.1016/j.ctrv.2022.102339.

2. Ellington T, Miller J, Henley S, Wilson R, Wu M, Richardson L. Trends in breast cancer incidence, by race, ethnicity, and age among women aged ≥20 years—United States, 1999–2018. MMWR Morb Mortal Wkly Rep. 2022;71(2):43–7. https://doi.org/10.15585/mmwr.mm7102a2.

3. McAndrew N. Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what’s to know in 2021. Curr Opin Obstet Gynecol. 2022;34(1):41–5. https://doi.org/10.1097/gco.0000000000000762.

4. Pusztai L, Yau C, Wolf D, Han H, Du L, Wallace A, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989-98.e5. https://doi.org/10.1016/j.ccell.2021.05.009.

5. Lu Y, Im S, Colleoni M, Franke F, Bardia A, Cardoso F, et al. Updated overall survival of ribociclib plus endocrine therapy vs endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2− advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res. 2021. https://doi.org/10.1158/1078-0432.Ccr-21-3032.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer;Clinical Breast Cancer;2024-07

2. Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation;Analytical Chemistry;2023-02-16